secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001628280-23-036179
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Therapeutics Q3 net loss narrows to $14.3M; cash runway into H1 2026
----------------------------------------------------------------------------

- Net loss $14.3M vs $25.8M YoY; collaboration revenue $17.5M incl. Merck termination.
- Cash, equivalents, marketable securities $259.9M as of Sept 30; runway into H1 2026.
- First patient dosed in FHD-286 combo study in AML; data expected H2 2024.
- Transitioned BRM Selective inhibitor program to Loxo@Lilly under collaboration.
- Preclinical data for EP300 and CBP selective degraders show tumor growth inhibition and no thrombocytopenia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828023036179/0001628280-23-036179-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828023036179/fhtx-20231102.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-036179

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer